Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions

The occurrence and development of coronary heart disease (CHD) are closely linked to fluctuations in blood glucose levels. While the efficacy of intensified treatment guided by HbA1c levels remains uncertain for individuals with diabetes and CHD, this review summarizes the findings and conclusions r...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jingyang, Yin, Dong, Dou, Kefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288803/
https://www.ncbi.nlm.nih.gov/pubmed/37349787
http://dx.doi.org/10.1186/s12933-023-01875-8
_version_ 1785062149061607424
author Chen, Jingyang
Yin, Dong
Dou, Kefei
author_facet Chen, Jingyang
Yin, Dong
Dou, Kefei
author_sort Chen, Jingyang
collection PubMed
description The occurrence and development of coronary heart disease (CHD) are closely linked to fluctuations in blood glucose levels. While the efficacy of intensified treatment guided by HbA1c levels remains uncertain for individuals with diabetes and CHD, this review summarizes the findings and conclusions regarding HbA1c in the context of CHD. Our review showed a curvilinear correlation between regulated level of HbA1c and therapeutic effectiveness of intensified glycemic control among patients with type 2 diabetes and coronary heart disease. It is necessary to optimize the dynamic monitoring indicators of HbA1c, combine genetic profiles, haptoglobin phenotypes for example and select more suitable hypoglycemic drugs to establish more appropriate glucose-controlling guideline for patients with CHD at different stage of diabetes.
format Online
Article
Text
id pubmed-10288803
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102888032023-06-24 Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions Chen, Jingyang Yin, Dong Dou, Kefei Cardiovasc Diabetol Review The occurrence and development of coronary heart disease (CHD) are closely linked to fluctuations in blood glucose levels. While the efficacy of intensified treatment guided by HbA1c levels remains uncertain for individuals with diabetes and CHD, this review summarizes the findings and conclusions regarding HbA1c in the context of CHD. Our review showed a curvilinear correlation between regulated level of HbA1c and therapeutic effectiveness of intensified glycemic control among patients with type 2 diabetes and coronary heart disease. It is necessary to optimize the dynamic monitoring indicators of HbA1c, combine genetic profiles, haptoglobin phenotypes for example and select more suitable hypoglycemic drugs to establish more appropriate glucose-controlling guideline for patients with CHD at different stage of diabetes. BioMed Central 2023-06-22 /pmc/articles/PMC10288803/ /pubmed/37349787 http://dx.doi.org/10.1186/s12933-023-01875-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Chen, Jingyang
Yin, Dong
Dou, Kefei
Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions
title Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions
title_full Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions
title_fullStr Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions
title_full_unstemmed Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions
title_short Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions
title_sort intensified glycemic control by hba1c for patients with coronary heart disease and type 2 diabetes: a review of findings and conclusions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288803/
https://www.ncbi.nlm.nih.gov/pubmed/37349787
http://dx.doi.org/10.1186/s12933-023-01875-8
work_keys_str_mv AT chenjingyang intensifiedglycemiccontrolbyhba1cforpatientswithcoronaryheartdiseaseandtype2diabetesareviewoffindingsandconclusions
AT yindong intensifiedglycemiccontrolbyhba1cforpatientswithcoronaryheartdiseaseandtype2diabetesareviewoffindingsandconclusions
AT doukefei intensifiedglycemiccontrolbyhba1cforpatientswithcoronaryheartdiseaseandtype2diabetesareviewoffindingsandconclusions

Ejemplares similares